Identifier-confirmed and citation-only records have not passed evidence or citation verification. These checks do not establish evidence strength, efficacy, safety, or suitability.
Read each study in its experimental context. A shared molecule name or database link does not establish that our material matches a study's formulation, composition or preparation. Study findings are not measurements of our inventory, promises of a biological result or authorization to use our materials in humans or animals. Actual Product specifications and lot reports are separate records.
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Minimum inhibitory concentration (MIC) assays were executed using a 96-well microdilution technique using the following four treatment groups: media only (control), Tβ4, ciprofloxacin, and Tβ4 + ciprofloxacin.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Platelet adhesion under shear was measured using a BioFlux200TM flow chamber system (Fluxion Biosciences Inc) according to the manufacturer's instructions.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Study scale: Fluorescence intensities were measured after a 1-h treatment with 10 μg/mL H2A, 1 μM LL-37, or both H2A and LL-37 (n = 6 for each condition); or with 1 μg/mL PMB or H2A and PMB (n = 3 for each condition).
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
We hypothesized that decreasing Mg2+ concentrations would destabilize the bacterial membrane, increasing H2A entry and bactericidal activity.
Study design
Not reported in the declared source.
Participants or experimental system
All the cells were harvested at mid-exponential growth phase and were cultured in buffered medium, which minimizes potential changes in pH.
Study scale
Fluorescence intensities were measured after a 1-h treatment with 10 μg/mL H2A, 1 μM LL-37, or both H2A and LL-37 (n = 6 for each condition); or with 1 μg/mL PMB or H2A and PMB (n = 3 for each condition).
Intervention or exposure
Bacteria were treated for 1 h before plating on non-selective LB agar plates.
Comparator
Fluorescence was distributed uniformly in untreated cells, indicating a diffuse bacterial chromosome (Fig. 5d).
Outcomes examined
Fluorescence intensities in (b) were measured after a 1-h treatment with H2A alone or in combination with Cam, Kan, LL-37, or PMB.
Key findings
Here we report that histone H2A enters E. coli and S. aureus through membrane pores formed by the AMPs LL-37 and magainin-2.
Limitations and uncertainty
H2A-treated cells showed consistently low PI fluorescence across the recovery period, indicating the lack of membrane damage by H2A. These results suggest that bacteria can repair membrane pores induced by LL-37 but the presence of H2A inhibits repair of LL-37-induced pores.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
We address this question by contrasting two methods of intranasal administration (a standard nasal spray, and a nebulizer expected to improve OT deposition in nasal areas putatively involved in direct nose-to-brain transport) to intravenous administration in terms of effects on regional cerebral blood flow during two hours post-dosing.
Study design
We employed a double-blind, placebo-controlled, triple-dummy, crossover design.
Participants or experimental system
We collected plasma samples at baseline and at five timepoints post-dosing to measure changes in the concentration of OT and perform pharmacokinetics analysis.
Study scale
Not reported in the declared source.
Intervention or exposure
Mean AUCs were compared between the three methods of administration with a repeated measures one-way analysis of variance, using the Greenhouse-Geisser correction against violations of sphericity.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
We demonstrate that OT-induced decreases in amygdala perfusion, a key hub of the OT central circuitry, are explained entirely by OT increases in systemic circulation following both intranasal and intravenous OT administration.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Antibacterial activity measured using killing assays.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
To test how abundant ChAT-VIP input to L1 interneurons is in mouse prefrontal cortical slices, we recorded from an additional set of 118 L1 interneurons and activated ChAT-VIP neurons with blue-light pulses.
Study design
Following acquisition of baseline performance, rats were assigned to the testing phase where the task comprised 100 consecutive trials with a random assignment of laser-ON or laser-OFF trials.
Participants or experimental system
Since ChAT-VIP cells release ACh in the mPFC, similar to basal forebrain (BF) cholinergic inputs, we also tested whether inhibiting ChAT-VIP interneurons affected attention behaviour distinct from inhibiting BF cholinergic inputs to mPFC.
Study scale
No GABAergic IPSCs at 0 mV were observed following light-evoked activation of ChAT-VIP interneurons (n = 0/8).
Intervention or exposure
To optimize rat BF injection location, as we previously did for mouse BF6, four BF coordinates were used: (a) AP −1.20 mm; ML 2.0 mm; DV −6.8 and 8.9 (1 μl in total) or −7.8 mm (0.5 μl) from skull; (b) AP −0.60 mm; ML 2.0 mm; DV −8.4 mm from skull; (c) AP 0.00 mm; ML 1.6 mm; −8.7 and −8.4 (1 μl in total) or −8.6 mm (0.5 μl) from skull; (d) AP + 0.84 mm; 0.9 mm; DV −7.9 and −8.3 (1 μl in total) or −8.1 mm (0.5 μl) from skull.
Comparator
For each animal, behavioural performance during laser-ON trials was compared with its own behavioural performance during laser-OFF trials.
Outcomes examined
GAD67 staining was performed with primary antibody anti-GAD67 raised in mouse (1:1200, MAB5406 clone 1G10.2, Chemicon Millipore) and visualized using donkey anti-mouse Alexa 546 (1:400, A10036, Molecular probe).
Key findings
Here, the authors report that ChAT-VIP subtype of interneurons directly excite pyramidal neurons in multiple layers via fast cholinergic neurotransmission.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Study scale: We compared the expression levels of LL-37 in 45 adjacent normal lung tissues and 86 NSCLC tissues (i.e., 47 adenocarcinomas and 39 squamous cell carcinomas) through immunohistochemistry.
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
We subsequently investigated the levels of LL-37 in the sera of healthy donors and patients diagnosed with NSCLC.
Study design
The animal model of wild-type and Cramp knockout mice was employed to evaluate the tumorigenic effect of LL-37 in non-small cell lung cancer.
Participants or experimental system
The human lung adenocarcinoma cell line A549 and mouse LLC cells were obtained from the American Type Culture Collection, and cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, USA), supplemented with 10% fetal calf serum (Invitrogen, Carlsbad, USA), 100 U/ml penicillin, and 100 U/ml streptomycin (PAA Laboratories GmbH).
Study scale
We compared the expression levels of LL-37 in 45 adjacent normal lung tissues and 86 NSCLC tissues (i.e., 47 adenocarcinomas and 39 squamous cell carcinomas) through immunohistochemistry.
Intervention or exposure
Transfection complexes were removed after 2 h, and cells were stimulated with LL-37 in DMEM supplemented with 0.5% fetal calf serum for 24 h.
Comparator
Treatment with LL-37 caused accumulation of unphosphorylated β-catenin in the nuclei of A549 cells versus untreated cells, exhibiting diffuse localization with a small fraction of unphosphorylated β-catenin in the nuclei (Figure 4D).
Outcomes examined
Methods: The expression of LL-37 in the tissues and sera of patients with non-small cell lung cancer was determined through immunohistological, immunofluorescence analysis, and enzyme-linked immunosorbent assay.
Key findings
Results: LL-37 produced by myeloid cells was frequently upregulated in primary human lung cancer tissues.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vivo/preclinical · Verification: Evidence verified by machine against declared source
Study scale: Fourteen days after the operation, rats (n = 10 SHAM and n = 24 BCCAO) were killed with anesthetic and the eyes were processed for histology.
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not reported in the declared source.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Fourteen days after the operation, rats (n = 10 SHAM and n = 24 BCCAO) were killed with anesthetic and the eyes were processed for histology.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: In vitro · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
To examine ASMase distribution on the apical surface of differentiated non-CF pHBEs, the above procedure was followed but without the membrane permeabilization step.
Study design
Not reported in the declared source.
Participants or experimental system
CF lung tissue was obtained from F508del/F508del patients after lung transplantation with informed written consent and following protocols approved by the Institutional Review Boards of the Institut de recherches cliniques de Montréal and McGill University.
Study scale
Not reported in the declared source.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
To visualize endogenous CFTR and the effects of VIP, cells were exposed bilaterally to control medium or medium containing 200 nM VIP (Sigma-Aldrich) for 1 h, then gently washed and scraped from the insert into PBS and centrifuged onto glass coverslips (500 rpm, 5 min; Cytospin 4; Thermo Fisher Scientific).
Outcomes examined
To measure short-circuit current (Isc), cells were seeded on fibronectin-coated polyester membrane inserts (0.4 µM pore diameter, 6.5 mm diameter; Corning Costar) and kept submerged until the transepithelial electrical resistance reached >400 Ω⋅cm2 as measured using an epithelial volt-ohmmeter (World Precision Instruments).
Key findings
These results demonstrate that CFTR is colocalized with motile cilia and reveal surprisingly robust regulation of CFTR distribution and lateral mobility, most likely through autocrine redox activation of extracellular ASMase.
Limitations and uncertainty
Although the clusters (in contrast to the platforms) were optical resolution–limited size in the images and this approach provides only an upper estimate of microdomain area, measuring the subdiffraction-sized aggregates more accurately would only strengthen our conclusion regarding the different dimensions of rafts versus platforms.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. Nothing is shown here and nothing is substituted for it.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Five articles (5,685 participants) were included in the current meta-analysis.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
Not published. Nothing is shown here and nothing is substituted for it.
Outcomes examined
Not published. Nothing is shown here and nothing is substituted for it.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Study scale: Subgroup analyses were performed according to Hunt and Hess grade (good grade ≤ 2, N = 216; poor grade ≥ 3, N = 246) and treatment procedure (clip or coil).
The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
The aim of this study was to evaluate the effect of Cerebrolysin in patients with aneurysmal SAH.
Study design
One of the limitations of this study was the retrospective design.
Participants or experimental system
Aneurysmal SAH patients who had their aneurysm obliterated at our institution from 2007 to 2016 were retrospectively studied.
Study scale
Subgroup analyses were performed according to Hunt and Hess grade (good grade ≤ 2, N = 216; poor grade ≥ 3, N = 246) and treatment procedure (clip or coil).
Intervention or exposure
Cerebrolysin was administered at daily doses of 30 ml for at least 3 days.
Comparator
Patients received Cerebrolysin treatment or standard care only (control group).
Outcomes examined
SAH sum score (0–30) was calculated as the mean of the Hijdra score, which is the sum of the amount of blood in ten cistern or fissure points (0–3 each).
Key findings
In good-grade patients (N = 216), clinical outcomes and mortality did not differ significantly between the control and Cerebrolysin groups.
Limitations and uncertainty
Further studies are needed to confirm our results.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked
Study type: Human research · Verification: Evidence verified by machine against declared source
Some fields are not published. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not reported in the declared source.
Study design
Not published. Nothing is shown here and nothing is substituted for it.
Participants or experimental system
Not published. Nothing is shown here and nothing is substituted for it.
Study scale
Not published. Nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. Nothing is shown here and nothing is substituted for it.
Comparator
To evaluate the efficacy and safety of Tongfu powder for external application on Shénquè (the umbilicus, hereafter, Tongfu powder) versus mosapride in acute pancreatitis (AP) patients with gastrointestinal dysfunction.
Outcomes examined
The endpoint of the study was death at 3 months.
Key findings
Not published. Nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not published. Nothing is shown here and nothing is substituted for it.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Summary: exact sentences from the abstract. Checked